Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Immutep Limited - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
IMMP
Nasdaq
2830
www.immutep.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Immutep Limited
Is Immutep Limited (IMMP) the Best Long Term ASX Stock to Buy Now?
- Feb 11th, 2025 4:55 pm
Immutep Quarterly Activities Report Q2 FY25
- Jan 31st, 2025 1:00 pm
Is Immutep Limited (IMMP) One of the Best ASX Stocks to Buy According to Hedge Funds?
- Jan 31st, 2025 12:30 pm
Why Immutep (IMMP) Is Among the Best Australian Stocks to Buy Now?
- Jan 27th, 2025 1:02 pm
Patient Enrolment Completed for EFTISARC-NEO Phase II Trial
- Jan 22nd, 2025 1:00 pm
Immutep Limited (ASX:IMM) is largely controlled by institutional shareholders who own 51% of the company
- Jan 15th, 2025 10:39 pm
Patient Enrolment Completed for INSIGHT-003
- Jan 6th, 2025 1:00 pm
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
- Dec 17th, 2024 1:00 pm
Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II
- Dec 16th, 2024 1:00 pm
Immutep announces results from Cohort B of TACTI-003 trial
- Dec 13th, 2024 1:20 pm
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
- Dec 12th, 2024 1:15 pm
Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
- Dec 10th, 2024 1:00 pm
Exclusive: Prima, Mexico-based manufacturing and supply chain integrator, reveals it has raised $42.5 million
- Dec 6th, 2024 11:59 am
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
- Nov 14th, 2024 1:15 pm
Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting
- Nov 14th, 2024 1:00 pm
Immutep (ASX:IMM) shareholders have endured a 51% loss from investing in the stock three years ago
- Nov 6th, 2024 8:34 pm
Immutep Quarterly Activities Report Q1 FY25
- Oct 29th, 2024 12:00 pm
Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024
- Oct 28th, 2024 12:00 pm
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial
- Oct 17th, 2024 12:00 pm
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
- Oct 10th, 2024 12:00 pm
Scroll